According to the Centers for Disease Control and Prevention [3], people with chronic respiratory diseases such as cystic fibrosis (CF) with and without lung transplantation (LTX) are at a higher risk for severe coronavirus-disease 2019 (COVID-19); however, the clinical course and recovery of people with CF (pwCF) after COVID-19 and the potential protective role of CF transmembrane conductance regulator (CFTR) therapy remains to be investigated [4]. This evidence concerns the gene CFTR and COVID-19.